Department of Pediatric Oncology, Hematology and Clinical Immunology, Heinrich-Heine Universität Düsseldorf, Medical Faculty, 40225, Düsseldorf, Germany.
J Clin Immunol. 2012 Jun;32(3):438-40. doi: 10.1007/s10875-012-9654-7. Epub 2012 Feb 23.
Allogeneic hematopoietic stem cell transplantation (HSCT) has not been a therapeutic option in ataxia telangiectasia (AT) due to overwhelming toxicity of conditioning in the context of the global DNA repair deficiency. Furthermore HSCT is unable to cure neurological involvement of AT. We report on a Turkish child with a Hyper IgM phenotype disorder, in which clinical aspects of AT were absent and thus, AT not diagnosed. He was transplanted with a reduced toxicity, but full intensity conditioning regimen comprising treosulfan, fludarabine and ATG. The peritransplant period was uneventful and the patient was discharged at day +57. 8 months after HSCT, the patient developed hepatopathy with monoclonal gammopathy of unclear significance and died due to hepatic failure and encephalopathy at the age of 32 months. Post mortem high throughput sequencing revealed a mutation in the ATM gene.
由于全基因组 DNA 修复缺陷,异基因造血干细胞移植(HSCT)在共济失调毛细血管扩张症(AT)中并不是一种治疗选择。此外,HSCT 无法治愈 AT 的神经病变。我们报告了一名土耳其患有高免疫球蛋白 M 表型障碍的儿童,该儿童没有 AT 的临床特征,因此未被诊断为 AT。他接受了低强度、但完全强度的预处理方案,包括曲奥舒凡、氟达拉滨和 ATG。移植期间无并发症,患者在 HSCT 后第+57 天出院。8 个月后,患者出现肝毒性,伴有意义未明的单克隆丙种球蛋白血症,并因肝衰竭和脑病在 32 个月大时死亡。死后高通量测序显示 ATM 基因突变。